Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Excitatory amino acids antagonists

Berry, S.C. Dawkins, S.L. and Lodge, D. Comparison of o-- and K -Opiate receptor ligands as excitatory amino acid antagonists. r J. Pharmacol 83 179-185, 1984b. [Pg.77]

Spinella M, Bodnar RJ. (1996). Excitatory amino acid antagonists in the rostro-ventral medulla inhibit mesencephalic morphine analgesia in rats. Pain. 64 545-52. [Pg.531]

Sveinbjornsdottir S, Sander JWAS, Upton D,etal(1993) The excitatory amino acid antagonist d-CPP-ene (sdz eaa-494) in patients with epilepsy. Epilepsy Res 16 165-174 Takano T, Lin JH, Arcnino G, et al (2001) Glntamate release promotes growth of malignant gliomas. Nat Med 7 1010-1015... [Pg.301]

Muir, K. W. and Lees, K. R. Clinical experience with excitatory amino acid antagonist drugs, Stroke 1995, 26, 503-513. [Pg.423]

Kawamata T., Katayama Y., Hovda D. A., Yoshino A., and Becker D. P. (1992) Administration of excitatory amino acid antagonists via microdialysis attenuates the increase in glucose utilization seen following concussive brain injury. J. Cereb. Blood Flow Metab. 12,12-24. [Pg.141]

Yamamoto T, Yaksh TL (1992) Spinal pharmacology of thermal hyperesthesia induced by constriction injury of sciatic nerve. Excitatory amino acid antagonists. Pain 49 121-128 Yamamoto Y, Ono H, Ueda A, Shimamura M, Nishimura K, Hazato T (2002b) Spinorphin as an endogenous inhibitor of enkephahn-degrading enzymes roles in pain and inflammation. Curr Protein Pept Sci 3 587-599... [Pg.532]

Rogawski, M.A. (1993) Therapeutic potential of excitatory amino acid antagonists Channel blockers and 2.3-ben xliaKpine. Trends Pharmacol. ScL. 14.325-331. [Pg.134]

Meldrum, B. S. (1991) Excitatory Amino Acid Antagonists, Blackwell, Oxford. [Pg.19]

Graham WC, Robertson RG, Sambrook MA et al (1990) Injection of excitatory amino acid antagonists into the medial pallidal segment of a l-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP) treated primate reverses motor symptoms of parkinsonism. Life Sci 47 PL91-PL97... [Pg.130]

Marek, P., Beneliyahu, S., Gold, M., Liebeskind, J.C., 1991. Excitatory amino acid antagonist (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat. Brain Res. 547, 77-81. [Pg.159]

McCullogh, J., 1992. Excitatory amino acid antagonists and their potential for the treatment of ischemic brain damage in man. Br. J. Clin. Pharmacol. 34, 106-114. [Pg.176]

De Sarro G, Ammendola D, Nava F, De Sarro A. Effects of some excitatory amino acid antagonists on imipenem-induced seizures in DBA/2 mice. Brain Res 1995 671 (1) 131 0. [Pg.502]

L-689,560 is an excitatory amino acid antagonist. It binds to but does not activate excitatory amino acid receptors, thereby blocking the actions of agonists. The drug is a selective antagonist for the glycine site on the A7-methyl-D-aspartate receptor. ... [Pg.1007]

Excitatory amino acid-receptor antagonists can provide neuroprotection in experimental models of hypoxia-ischemia 565... [Pg.559]

Opioids also interact with excitatory amino acid neurotransmitters. At lower micromolar concentrations, p agonists (e.g., DAMGO) enhance NMDA activity in the nucleus accumbens, but inhibit non-NMDA activity (Martin et al. 1997). At higher concentrations (5 pM), NMDA currents are reduced. Conversely, central administration of glutamate can precipitate a withdrawal syndrome in morphine-dependent animals, similar to the opioid antagonist naloxone. NMDA mechanisms also appear to be involved in the development of morphine tolerance. Competitive and noncompetitive NMDA antagonists and inhibitors of nitric oxide synthase reduce or eliminate tolerance to morphine (Elliott et al. 1995 Bilsky et al. 1996). However, this does not occur for tolerance to k opioids. Pharmacokinetics... [Pg.307]

Panter S, Faden A. 1992. Pretreatment with NMDA antagonists limits release of excitatory amino acids following traumatic brain injury. Neurosci Lett 136(2) 165-168. [Pg.251]

In addition to epilepsy, neuronal death due to the toxic effects of glutamate has also been implicated in cerebral ischaemia associated with multi-infarct dementia and possibly Alzheimer s disease. With the plethora of selective excitatory amino acid receptor antagonists currently undergoing development, some of which are already in clinical trials, one may expect definite advances in the drug treatment of neurodegenerative disorders in the near future. [Pg.60]

Pharmacology Persistent activation of CNS N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer disease. Memantine is an NMDA receptor antagonist. [Pg.1144]

Histamine Hi receptor antagonists which enter the brain (diphenhydramine, promethazine and others) have sedative actions and polysomnographic recordings have shown that they suppress REM sleep and modestly increase SWS. A rebound in REM sleep sometimes occurs on discontinuation. Stimulation of central Hi and H2 receptors markedly potentiates signals produced by excitatory amino acids and it has been suggested that histamine acts as a waking amine (Schwartz et al., 1986). The effects of centrally acting antihistamines on sleep may be due to inhibition of these effects. [Pg.166]

Meldrum B (1985) Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters. Clin Sci 68 113-122... [Pg.295]

See other pages where Excitatory amino acids antagonists is mentioned: [Pg.251]    [Pg.242]    [Pg.288]    [Pg.741]    [Pg.519]    [Pg.49]    [Pg.217]    [Pg.264]    [Pg.135]    [Pg.251]    [Pg.242]    [Pg.288]    [Pg.741]    [Pg.519]    [Pg.49]    [Pg.217]    [Pg.264]    [Pg.135]    [Pg.75]    [Pg.217]    [Pg.222]    [Pg.516]    [Pg.90]    [Pg.163]    [Pg.557]    [Pg.289]    [Pg.565]    [Pg.89]    [Pg.300]    [Pg.470]    [Pg.312]    [Pg.417]    [Pg.422]    [Pg.70]    [Pg.71]    [Pg.299]    [Pg.301]   
See also in sourсe #XX -- [ Pg.240 ]



SEARCH



Amino Acid Antagonists

Excitatory

© 2024 chempedia.info